Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice (Q40922638)

24 September 2017

title

Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice (English)

1 reference

24 September 2017

E McKinnon

1 reference

24 September 2017

A Castley

1 reference

24 September 2017

L Payne

1 reference

24 September 2017

S Pummer

1 reference

24 September 2017

D Nolan

1 reference

24 September 2017

publication date

4 November 2015

1 reference

24 September 2017

1 reference

24 September 2017

1 reference

24 September 2017

1 reference

24 September 2017

page(s)

495-504

1 reference

Viral load assay sensitivity and low level viremia in HAART treated HIV patients

24 September 2017

cites work

1 reference

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

21 January 2018

1 reference

HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

21 January 2018

1 reference

Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.

21 January 2018

1 reference

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

21 January 2018

1 reference

Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation

21 January 2018

1 reference

HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens

21 January 2018

1 reference

Causes and consequences of incomplete HIV RNA suppression in clinical trials

21 January 2018

1 reference

Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting

21 January 2018

1 reference

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay

21 January 2018

1 reference

Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

21 January 2018

1 reference

Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells

21 January 2018

1 reference

Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral Therapy

21 January 2018

1 reference

HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy

21 January 2018

1 reference

Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART

21 January 2018

1 reference

Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up

21 January 2018

1 reference

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/HIV.12323

1 reference

24 September 2017

1 reference